company background image
KDMN

Kadmon HoldingsNasdaqGS:KDMN Stock Report

Last Price

US$9.50

Market Cap

US$1.7b

7D

0.4%

1Y

186.1%

Updated

09 Nov, 2021

Data

Company Financials +
KDMN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

KDMN Stock Overview

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Kadmon Holdings
Historical stock prices
Current Share PriceUS$9.50
52 Week HighUS$9.50
52 Week LowUS$3.29
Beta1.12
1 Month Change7.22%
3 Month Change84.47%
1 Year Change186.15%
3 Year Change274.02%
5 Year Change49.14%
Change since IPO-2.06%

Recent News & Updates

Sep 09

Kadmon, The Big Short

Kadmon is one of the highest shorted tickers on NASDAQ. Even a major drug approval didn't change that attitude. Sanofi is paying more than twice the current market cap to acquire KDMN. Run, baby, run.

Aug 04
Is Kadmon Holdings (NASDAQ:KDMN) Weighed On By Its Debt Load?

Is Kadmon Holdings (NASDAQ:KDMN) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Aug 02

Kadmon: What Will Lead To A Short Squeeze

Despite an approval, Kadmon hasn’t done as well as it should. The criminal pasts of its founders have been used as a way to keep it down. 2-4 quarters of solid revenues should change all that.

Shareholder Returns

KDMNUS BiotechsUS Market
7D0.4%-5.9%-3.5%
1Y186.1%-18.4%10.2%

Return vs Industry: KDMN exceeded the US Biotechs industry which returned 13.2% over the past year.

Return vs Market: KDMN exceeded the US Market which returned 30.9% over the past year.

Price Volatility

Is KDMN's price volatile compared to industry and market?
KDMN volatility
KDMN Average Weekly Movement20.6%
Biotechs Industry Average Movement10.1%
Market Average Movement6.6%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: KDMN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: KDMN's weekly volatility has increased from 13% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010127Harlan Waksalhttps://www.kadmon.com

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson’s disease.

Kadmon Holdings Fundamentals Summary

How do Kadmon Holdings's earnings and revenue compare to its market cap?
KDMN fundamental statistics
Market CapUS$1.70b
Earnings (TTM)-US$122.40m
Revenue (TTM)US$19.67m

86.2x

P/S Ratio

-13.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KDMN income statement (TTM)
RevenueUS$19.67m
Cost of RevenueUS$993.00k
Gross ProfitUS$18.68m
ExpensesUS$141.08m
Earnings-US$122.40m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.69
Gross Margin94.95%
Net Profit Margin-622.36%
Debt/Equity Ratio1,664.2%

How did KDMN perform over the long term?

See historical performance and comparison

Valuation

Is Kadmon Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: KDMN ($9.5) is trading below our estimate of fair value ($50.82)

Significantly Below Fair Value: KDMN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: KDMN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: KDMN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KDMN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KDMN has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Future Growth

How is Kadmon Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

67.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KDMN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KDMN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KDMN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KDMN's revenue (65.7% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: KDMN's revenue (65.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KDMN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Kadmon Holdings performed over the past 5 years?

15.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KDMN is currently unprofitable.

Growing Profit Margin: KDMN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KDMN is unprofitable, but has reduced losses over the past 5 years at a rate of 15.2% per year.

Accelerating Growth: Unable to compare KDMN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KDMN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (36.3%).


Return on Equity

High ROE: KDMN has a negative Return on Equity (-853.73%), as it is currently unprofitable.


Financial Health

How is Kadmon Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: KDMN's short term assets ($281.8M) exceed its short term liabilities ($44.6M).

Long Term Liabilities: KDMN's short term assets ($281.8M) exceed its long term liabilities ($245.7M).


Debt to Equity History and Analysis

Debt Level: KDMN's debt to equity ratio (1664.2%) is considered high.

Reducing Debt: KDMN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KDMN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if KDMN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Kadmon Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KDMN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KDMN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KDMN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KDMN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KDMN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Harlan Waksal (68 yo)

7.25yrs

Tenure

US$1,215,451

Compensation

Dr. Harlan W. Waksal, M.D., has been the Chief Executive Officer and President of Kadmon Holdings, Inc. since September 2014. Dr. Waksal has been the President and Sole Proprietor of Waksal Consulting L.L....


CEO Compensation Analysis

Compensation vs Market: Harlan's total compensation ($USD1.22M) is below average for companies of similar size in the US market ($USD3.41M).

Compensation vs Earnings: Harlan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: KDMN's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: KDMN's board of directors are considered experienced (8.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.


Top Shareholders

Company Information

Kadmon Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Kadmon Holdings, Inc.
  • Ticker: KDMN
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.696b
  • Shares outstanding: 178.52m
  • Website: https://www.kadmon.com

Number of Employees


Location

  • Kadmon Holdings, Inc.
  • 450 East 29th Street
  • New York
  • New York
  • 10016
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/09 23:14
End of Day Share Price2021/11/08 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.